



## Advanced Control Formulary™ Change Summary Report Effective 10-01-2021

This report highlights all changes (additions, deletions and removals) to the CVS Caremark® Advanced Control Formulary.

### ADDITIONS:

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
<b>Brand Agents:</b>			
<b>Calquence</b> (acalabrutinib) oral capsule	Antineoplastic Agents/ Kinase Inhibitors	Calquence is indicated for the treatment of adult patients with: <ul style="list-style-type: none"><li>• Mantle cell lymphoma (MCL) who have received at least one prior therapy</li><li>• Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)</li></ul>	To provide an additional option for the treatment of MCL, CLL, and SLL.
<b>Koselugo</b> (selumetinib) oral capsule	Antineoplastic Agents/ Kinase Inhibitors	Koselugo is indicated for the treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN).	To provide an option for the treatment of NF1.
<b>Tagrisso</b> (osimertinib) oral tablet	Antineoplastic Agents/ Kinase Inhibitors	Tagrisso is indicated for: <ul style="list-style-type: none"><li>• As adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test</li><li>• The first-line treatment of adult patients with metastatic NSCLC whose tumors</li></ul>	To provide an option for the treatment of NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations and metastatic NSCLC with EGFR T790M mutations.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2021 CVS Caremark. All rights reserved.

## Advanced Control Formulary™ Change Summary Report Effective 10-01-2021

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
		have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test <ul style="list-style-type: none"> <li>The treatment of adult patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, whose disease has progressed on or after EGFR tyrosine kinase inhibitor therapy</li> </ul>	
<b>Generic Agents:</b>			
<b>abacavir</b> oral solution	Anti-Infectives/ Antiretroviral Agents/ Nucleoside Reverse Transcriptase Inhibitors	Abacavir solution is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus 1 (HIV-1) infection.	To provide an additional generic option for the treatment of HIV-1 infection.
<b>azelastine-fluticasone</b> intranasal spray	Respiratory/ Nasal Steroids/Combinations	Azelastine-fluticasone is indicated for the relief of symptoms of seasonal allergic rhinitis in adult and pediatric patients 6 years of age and older.	To provide a generic nasal steroid and antihistamine combination option for the treatment of seasonal allergic rhinitis.
<b>brinzolamide</b> ophthalmic suspension	Topical/ Ophthalmic/ Carbonic Anhydrase Inhibitors	Brinzolamide is indicated for in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.	To provide an additional generic option for the treatment of elevated intraocular pressure.
<b>emtricitabine-tenofovir disoproxil fumarate</b> oral tablet	Anti-Infectives/ Antiretroviral Agents/ Antiretroviral Combinations	Emtricitabine-tenofovir disoproxil fumarate is indicated: <ul style="list-style-type: none"> <li>In combination with other antiretroviral agents for the treatment of HIV-1</li> </ul>	To provide an additional generic option for the treatment of HIV-1 infection and PrEP.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.  
©2021 CVS Caremark. All rights reserved.

Advanced Control Formulary™  
 Change Summary Report  
 Effective 10-01-2021

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
		infection in adults and pediatric patients weighing at least 17 kg <ul style="list-style-type: none"> <li>In at-risk adults and adolescents weighing at least 35 kg for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection</li> </ul>	
<b>lubiprostone</b> oral capsule	Gastrointestinal/ Irritable Bowel Syndrome	Lubiprostone is indicated for the treatment of: <ul style="list-style-type: none"> <li>Chronic idiopathic constipation (CIC) in adults</li> <li>Opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation</li> <li>Irritable bowel syndrome with constipation (IBS-C) in women ≥ 18 years old</li> </ul>	To provide a generic option for the treatment of CIC, OIC, and IBS-C.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.  
 ©2021 CVS Caremark. All rights reserved.

**DELETIONS:**

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
<b>Brand Agents:</b>			
<b>Dymista</b> (azelastine-fluticasone) intranasal spray	Respiratory/ Nasal Steroids/Combinations	Dymista is indicated for the relief of symptoms of seasonal allergic rhinitis in adult and pediatric patients 6 years of age and older.	Availability of additional nasal steroid and nasal steroid/antihistamine combination options for the treatment of allergic rhinitis.  Preferred options on the Advanced Control Formulary include azelastine-fluticasone, flunisolide, fluticasone and mometasone.
<b>Truvada</b> (emtricitabine-tenofovir disoproxil fumarate) oral tablet	Anti-Infectives/ Antiretroviral Agents/ Antiretroviral Combinations	Truvada is indicated: <ul style="list-style-type: none"> <li>• In combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 17 kg</li> <li>• In at-risk adults and adolescents weighing at least 35 kg for PrEP to reduce the risk of sexually acquired HIV-1 infection</li> </ul>	Availability of additional options for the treatment of HIV-1 infection and PrEP.  Preferred options on the Advanced Control Formulary include abacavir-lamivudine, emtricitabine-tenofovir disoproxil fumarate, lamivudine-zidovudine, Cimduo (lamivudine-tenofovir disoproxil fumarate), Descovy (emtricitabine-tenofovir alafenamide) and Temixys (lamivudine-tenofovir disoproxil fumarate).

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.  
 ©2021 CVS Caremark. All rights reserved.

**REMOVALS:**

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
<b>Brand Agents:</b>			
<b>Betamethasone acetate- betamethasone sodium phosphate</b> (betamethasone acetate-betamethasone sodium phosphate) suspension for injection	Endocrine and Metabolic/ Glucocorticoids	Betamethasone acetate-betamethasone sodium phosphate is used to treat many different inflammatory conditions, including asthma, allergies, ulcerative colitis, arthritis, systemic lupus erythematosus, and multiple sclerosis.	Availability of additional glucocorticoid options.  Preferred options on the Advanced Control Formulary include dexamethasone, hydrocortisone, methylprednisolone, prednisolone solution and prednisone.
<b>Calcipotriene foam</b> (calcipotriene) topical aerosol	Topical/ Dermatology/ Antipsoriatics	Calcipotriene foam is indicated for the topical treatment of plaque psoriasis of the scalp and body in adults and pediatric patients 4 years of age and older.	Availability of additional topical options for the treatment of plaque psoriasis.  Preferred options on the Advanced Control Formulary include calcipotriene ointment and calcipotriene solution.
<b>Cordran</b> (flurandrenolide) topical cream, topical lotion	Topical/ Dermatology/ Corticosteroids/ Low Potency	Cordran is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.	Availability of additional low potency topical corticosteroid options.  Preferred options on the Advanced Control Formulary include desonide and hydrocortisone.
<b>Heparin sodium in 5% dextrose</b> (heparin) intravenous solution for injection	Hematologic/ Anticoagulants/ Injectable	Heparin sodium in 5% dextrose is indicated for: <ul style="list-style-type: none"> <li>• Prophylaxis and treatment of venous thrombosis and pulmonary embolism</li> </ul>	Availability of additional injectable anticoagulant options.  Preferred options on the Advanced Control Formulary include enoxaparin and fondaparinux.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.  
 ©2021 CVS Caremark. All rights reserved.

Advanced Control Formulary™  
 Change Summary Report  
 Effective 10-01-2021

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
		<ul style="list-style-type: none"> <li>• Prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation</li> <li>• Treatment of acute and chronic consumption coagulopathies (disseminated intravascular coagulation)</li> <li>• Prevention of clotting in arterial and cardiac surgery</li> <li>• Prophylaxis and treatment of peripheral arterial embolism</li> <li>• Anticoagulant use in blood transfusions, extracorporeal circulation and dialysis procedures</li> </ul>	
<b>Ultravate</b> (halobetasol propionate) topical lotion	Topical/ Dermatology/ Corticosteroids/ Very High Potency	Ultravate indicated for the topical treatment of plaque psoriasis in patients 12 years of age and older.	Availability of additional very high potency topical corticosteroid options.  Preferred options on the Advanced Control Formulary include clobetasol cream, clobetasol foam, clobetasol gel, clobetasol lotion and clobetasol ointment.
<b>Generic Agents:</b>			
<b>betamethasone acetate- betamethasone sodium phosphate (NDC 71283062002 only)</b>	Endocrine and Metabolic/ Glucocorticoids	Betamethasone acetate-betamethasone sodium phosphate is used to treat many different inflammatory conditions, including asthma, allergies, ulcerative colitis, arthritis, systemic lupus erythematosus, and multiple sclerosis.	Availability of additional glucocorticoid options.  Preferred options on the Advanced Control Formulary include dexamethasone, hydrocortisone, methylprednisolone, prednisolone solution and prednisone.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.  
 ©2021 CVS Caremark. All rights reserved.

## Advanced Control Formulary™ Change Summary Report Effective 10-01-2021

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
suspension for injection			
<b>calcipotriene foam</b> topical aerosol	Topical/ Dermatology/ Antipsoriatics	Calcipotriene foam is indicated for the topical treatment of plaque psoriasis of the scalp and body in adults and pediatric patients 4 years of age and older.	Availability of additional topical options for the treatment of plaque psoriasis.  Preferred options on the Advanced Control Formulary include calcipotriene ointment and calcipotriene solution.
<b>chlordiazepoxide-clidinium (NDCs 67877073101, 70700018501)</b> oral capsule	Gastrointestinal/ Antispasmodics	Chlordiazepoxide-clidinium: <ul style="list-style-type: none"> <li>• Is indicated to control emotional and somatic factors in gastrointestinal disorders</li> <li>• May also be used as adjunctive therapy in the treatment of:               <ul style="list-style-type: none"> <li>○ Peptic ulcer</li> <li>○ Irritable bowel syndrome</li> <li>○ Acute enterocolitis</li> </ul> </li> </ul>	Availability of additional antispasmodic options.  Preferred options on the Advanced Control Formulary include dicyclomine, hyoscyamine sulfate and hyoscyamine sulfate orally disintegrating tablet.
<b>doxycycline hyclate delayed-rel tablet 100 mg</b> oral delayed-release tablet	Anti-Infectives/ Antibacterials/ Tetracyclines	Doxycycline hyclate delayed-rel tablet 100 mg is indicated for: <ul style="list-style-type: none"> <li>• Rickettsial infections</li> <li>• Sexually transmitted infections</li> <li>• Respiratory tract infections</li> <li>• Certain bacterial infections (e.g., urinary tract infections, relapsing fever, cholera)</li> <li>• Ophthalmic infections (e.g., trachoma, inclusion conjunctivitis)</li> <li>• Anthrax, including inhalational anthrax (post-exposure)</li> </ul>	Availability of additional tetracycline options.  Preferred options on the Advanced Control Formulary include doxycycline hyclate capsule, doxycycline hyclate tablet (except doxycycline hyclate tablet 50 mg [NDC 72143021160 only], 75 mg, 150 mg), minocycline and tetracycline.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.  
©2021 CVS Caremark. All rights reserved.

Advanced Control Formulary™  
 Change Summary Report  
 Effective 10-01-2021

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
		<ul style="list-style-type: none"> <li>Alternative treatment for selected infections (e.g., syphilis, actinomycosis) when penicillin is contraindicated</li> <li>Adjunctive therapy in acute intestinal amebiasis and severe acne</li> <li>Prophylaxis of malaria</li> </ul>	
<b>heparin sodium in 5% dextrose</b> intravenous solution for injection	Hematologic/ Anticoagulants/ Injectable	Heparin sodium in 5% dextrose is indicated for: <ul style="list-style-type: none"> <li>Prophylaxis and treatment of venous thrombosis and pulmonary embolism</li> <li>Prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation</li> <li>Treatment of acute and chronic consumption coagulopathies (disseminated intravascular coagulation)</li> <li>Prevention of clotting in arterial and cardiac surgery</li> <li>Prophylaxis and treatment of peripheral arterial embolism</li> <li>Anticoagulant use in blood transfusions, extracorporeal circulation and dialysis procedures</li> </ul>	Availability of additional injectable anticoagulant options.  Preferred options on the Advanced Control Formulary include enoxaparin and fondaparinux.
<b>meloxicam capsule</b> oral capsule	Analgesics/ NSAIDs	Meloxicam capsule is indicated for management of osteoarthritis pain.	Availability of additional oral NSAID options.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.  
 ©2021 CVS Caremark. All rights reserved.





Advanced Control Formulary™  
Change Summary Report  
Effective 10-01-2021

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
			Preferred options on the Advanced Control Formulary include diclofenac sodium, ibuprofen, meloxicam tablet and naproxen (except naproxen CR or naproxen suspension).
<b>paroxetine HCl ext-rel 37.5 mg (NDC 60505367503 only)</b> oral extended-release tablet	Central Nervous System/ Antidepressants/ Selective Serotonin Reuptake Inhibitors (SSRIs)	Paroxetine HCl ext-rel is indicated for use in adults for the treatment of <ul style="list-style-type: none"><li>• Major Depressive Disorder (MDD)</li><li>• Panic Disorder (PD)</li><li>• Social Anxiety Disorder (SAD)</li><li>• Premenstrual Dysphoric Disorder (PMDD)</li></ul>	Availability of additional SSRI options.  Preferred options on the Advanced Control Formulary include citalopram, escitalopram, fluoxetine (except fluoxetine tablet 60 mg, fluoxetine tablet [generics for Sarafem]), paroxetine HCl, paroxetine HCl ext-rel (except NDC 60505367503), sertraline and Trintellix (vortioxetine).

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.  
©2021 CVS Caremark. All rights reserved.